Mao Jian-Hua, Kim Il-Jin, Wu Di, Climent Joan, Kang Hio Chung, DelRosario Reyno, Balmain Allan
Cancer Research Institute, University of California at San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Science. 2008 Sep 12;321(5895):1499-502. doi: 10.1126/science.1162981.
The enzyme mTOR (mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein. Here, we show that mTOR is targeted for ubiquitination and consequent degradation by binding to the tumor suppressor protein FBXW7. Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR. Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.
酶mTOR(雷帕霉素的哺乳动物靶点)是治疗包括癌症在内的多种人类疾病的主要治疗干预靶点,但对于控制mTOR蛋白水平的过程却知之甚少。在此,我们表明mTOR通过与肿瘤抑制蛋白FBXW7结合而成为泛素化及随后降解的靶点。人乳腺癌细胞系和原发性肿瘤显示出FBXW7缺失与PTEN(磷酸酶和张力蛋白同源物)缺失或突变之间的相互关系,PTEN也可激活mTOR。携带FBXW7缺失或突变的肿瘤细胞系对雷帕霉素治疗特别敏感,这表明FBXW7缺失可能是对mTOR通路抑制剂治疗敏感的人类癌症的生物标志物。